PCSKP Inhibitor Achieves LDL-C Goals for Patients With High Risk for Cardiovascular Disease
Lerodalcibep reduced low-density lipoprotein-cholesterol (LDL-C) of 50–60% at week 52 of the phase 3 LIBerate-HR trial.
Read MoreApr 26, 2024
Lerodalcibep reduced low-density lipoprotein-cholesterol (LDL-C) of 50–60% at week 52 of the phase 3 LIBerate-HR trial.
Read MoreApr 12, 2024
Dr. Kathryn Kaiser explains the importance of investigating genetic associations within demographic groups to better understand and address health disparities.
Read MoreMar 24, 2024
Control of risk factors such as dyslipidemia and diabetes reduces the association between cardiovascular disease and HIV, new research shows.
Read MoreMar 20, 2024
Cardio-oncology rehabilitation models can potentially be incorporated into the standard care for cancer survivors facing high cardiovascular risk.
Read MoreJan 7, 2024
A single subcutaneous injection of lepodisiran resulted in substantial lipoprotein(a) reduction in the phase 1 trial.
Read MoreAug 16, 2022
One of the main reasons for mortality in people with autosomal dominant polycystic kidney disease...
Read MoreJan 26, 2022
The presence of cardiovascular disease (CVD) comorbidities and type 2 diabetes (T2D) increased the...
Read More